If you have read anything about Selank online, you have probably seen it framed as a "benzodiazepine alternative" — same calm, none of the sedation, dependence or memory fog. It is a tidy story, and it is built on a misreading of the peptide's own clinical record. Because the most recent human trial of Selank did not test it instead of a benzodiazepine. It tested it alongside one.

That distinction matters more than almost anything else in the Selank research literature, and it changes what the evidence can honestly be said to support. Here is what the trials actually did, what the newest preclinical work adds, and where Selank sits legally in Australia.

What is Selank, briefly

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is an analogue of tuftsin — a short immunoregulatory fragment of the immunoglobulin G heavy chain — extended at the C-terminus with Pro-Gly-Pro to slow enzymatic breakdown. It is registered in Russia as a prescription treatment for mild anxiety and is typically given intranasally. It is approved nowhere else. There is a fuller profile on our Selank page and the wider peptides index.

The 2015 trial was an add-on study, not a replacement study

The newest human trial in the public literature is Medvedev and colleagues (2015), published in the Russian journal Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. The design compared monotherapy with phenazepam — a benzodiazepine used in Russia and not marketed in Australia — against phenazepam plus Selank in patients with anxiety-phobic, hypochondriacal and somatoform disorders.

The reported findings were that the benzodiazepine's effect arrived earlier when Selank was added, and that the combination reduced unwanted benzodiazepine effects — attention and memory impairment, asthenia and sedation — both during treatment and after the tranquilliser was withdrawn.

Read that carefully. The trial's own conclusion is that Selank may extend the therapeutic possibilities of benzodiazepine treatment. It is an adjunct hypothesis. It is not evidence that Selank replaces a benzodiazepine, and it cannot be, because there was no arm in which patients received Selank alone.

Why the marketing inverted it

The inversion is easy to see how it happened. An add-on trial that reports "fewer benzodiazepine side effects" gets compressed online into "Selank gives you benzodiazepine benefits without the side effects." Those are different claims. The first is about a combination; the second is about a substitution nobody in that trial performed.

The rest of the human evidence: three small trials, none placebo-controlled

The Selank human dataset is genuinely thin, and any Selank research summary that suggests otherwise is overstating it.

The most-cited trial is Zozulya, Neznamov and colleagues (2008), which enrolled 62 patients with generalised anxiety disorder and neurasthenia — roughly 30 on Selank, 32 on the benzodiazepine medazepam. Anxiolytic effect was rated on the Hamilton, Zung and Clinical Global Impression scales, and the authors also reported an increase in serum leu-enkephalin half-life that tracked with symptom reduction, which is where the "enkephalinase inhibition" mechanism claim originates.

Note what that design is: an active-comparator study with no placebo arm. In an indication as placebo-responsive as generalised anxiety, that is a real limitation. A third published comparison looked at Selank versus phenazepam. All three are small, all three are Russian, all three are decades-adjacent to each other, and none has been independently replicated outside Russia. Claims circulating online about Selank having "over 800 patients" of clinical data do not match the published record we could locate.

The newest data is in mice — and it's still about the combination

The most recent primary work of note is a 2025 paper in Neurochemical Journal examining combined benzodiazepine and Selank treatment in male BALB/c mice bred for elevated baseline anxiety. Combining Selank with diazepam or mezapam increased open-arm entries and time in the elevated plus maze compared with the tranquilliser alone, and Selank prevented the drop in locomotor activity produced by therapeutic doses of diazepam or olanzapine — though notably not haloperidol.

This is animal data. Elevated plus maze behaviour in a mouse strain is not an anxiety outcome in a person. But it is worth flagging that the newest research direction for Selank is, once again, the combination question rather than the standalone one — and that the proposed mechanism is allosteric modulation of GABAergic signalling, not direct occupancy of the benzodiazepine binding site.

There is a practical corollary here that deserves plain language: if the entire modern research interest in Selank concerns how it interacts with prescribed sedatives, then self-experimenting with it while taking a benzodiazepine is precisely the scenario with the least room for guesswork. Benzodiazepine tapering in Australia is a supervised clinical process for good reason.

Is Selank legal in Australia?

Selank sits in the same awkward position as most research peptides here, and it's worth stating precisely.

Selank is not scheduled in the Poisons Standard — it is not named as a Schedule 4 prescription-only substance. That is not the same as being approved. Selank is not on the Australian Register of Therapeutic Goods, which makes it an unapproved therapeutic good the moment it is supplied or promoted for human use. Supplying or advertising it for a therapeutic purpose engages the Therapeutic Goods Act regardless of its unscheduled status.

The TGA has issued explicit warnings about the risks of importing unapproved peptide products promoted online, including products arriving via the Personal Importation Scheme, noting that these can pose significant safety risks — purity, identity and sterility among them. Guidance for practitioners on importing, compounding and supplying unapproved peptides has been published separately.

On the anti-doping side: Selank does not appear on the WADA 2026 Prohibited List. That is a statement about doping status only. It says nothing about safety, efficacy or legality of supply.

For updates as this evidence base moves, join the free list.

The honest summary

Selank has a plausible mechanism, an unusual regulatory history, a decent tolerability signal in the small studies that exist, and a genuinely interesting adjunct hypothesis. What it does not have is a placebo-controlled trial, a replication outside Russia, or a single human study in which it was tested as a standalone substitute for a benzodiazepine. Anyone selling it as one is describing a trial that has not been run.

FAQ

What is Selank used for?

In Russia, Selank is registered as a prescription treatment for mild anxiety and is administered intranasally. It is not approved in Australia, the US or the EU, and the published human evidence consists of three small Russian trials, the most recent from 2015.

Is Selank a benzodiazepine alternative?

No human trial has tested that. The 2015 study compared a benzodiazepine alone against the same benzodiazepine plus Selank — an add-on design — and the 2008 study used a benzodiazepine as an active comparator with no placebo arm. The "alternative" framing goes beyond the data.

Is Selank legal in Australia?

Selank is unscheduled in the Poisons Standard but is not on the ARTG, making it an unapproved therapeutic good when supplied or promoted for human use. The TGA has warned about the risks of importing unapproved peptide products online.

Is Selank banned by WADA?

Selank does not appear on the WADA 2026 Prohibited List. That relates to anti-doping status only and is not an indication that it is safe, effective or lawful to supply in Australia.

Sources

This article is independent editorial information, not medical advice. Selank is an unapproved therapeutic good in Australia — it is not on the ARTG and is not approved for any use here. Speak with a qualified health practitioner about anxiety treatment or benzodiazepine tapering.